Skip to content

LCI-PED-NOS-EXER-001: Exercise in Pediatric Oncology Patients

LCI-PED-NOS-EXER-001: Just Move. A Randomized Controlled Trial Investigating Exercise in Pediatric Oncology Patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05058508
Enrollment
60
Registered
2021-09-27
Start date
2024-03-11
Completion date
2027-11-01
Last updated
2026-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Cancer

Keywords

Exercise, Pediatric Oncology

Brief summary

The purpose of this study is to see if there are physical and emotional benefits to participating in a structured exercise regimen for those who are ages 2-25, are newly diagnosed with a blood or solid tumor cancer, and are currently undergoing or will begin cancer treatment.

Detailed description

This is a randomized, controlled trial to investigate if a structured exercise regimen will have benefit relative to the control arm by increasing and /or maintaining physical functioning in pediatric subjects undergoing chemotherapy and childhood cancer treatment as measured by 6-Minute Walk test and BOT-2 Brief or PDMS-2.

Interventions

OTHER"Just Move" Exercise

Subjects complete "Just Move" Exercises Five Times Per Week

Subjects exercise/move as tolerated

Sponsors

Wake Forest University Health Sciences
Lead SponsorOTHER
Atrium Health Levine Cancer Institute
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
2 Years to 25 Years
Healthy volunteers
No

Inclusion criteria

1. Ages 2-25 at time of consent 2. Subject has newly diagnosed cancer per Investigator, and is planning to undergo chemotherapy for treatment of malignancy for at least 3 full cycles 3. Ability of subject (and/or parent/guardian) to read and understand the English or Spanish language 4. As determined and documented by the enrolling investigator, ability of the subject to understand and comply with study procedures for the entire length of the study 5. Subject has newly diagnosed cancer per Investigator and is planning to undergo chemotherapy, immunotherapy, or other systemically delivered for treatment of malignancy. Subjects are allowed to be enrolled up to 21 days after initiating cancer treatment. 6. Receiving oncologic care at Levine Children's Cancer and Blood Disorders Clinic. 7. Subject is anticipated to receive at least 3 full cycles of chemotherapy or other systemic cancer treatment. 8. Not participating in another clinical trial that precludes participating in additional nondrug clinical trials.

Exclusion criteria

1. Known cardiac dysfunction that, in the opinion of the investigator, would be unsafe for the child to participate in the exercise program 2. Any other uncontrolled intercurrent illness/medical condition or psychiatric illness/social situations that would limit compliance with study requirements or would be considered unsafe for the child to participate as determined by the Investigator. 3. Recent (within 4 weeks of enrollment) or planned surgery that will result in prolonged limited mobility not amendable to exercise modifications per investigator discretion 4. Primary CNS Tumor 5. Osteosarcoma

Design outcomes

Primary

MeasureTime frameDescription
Potential benefit of increasing/maintaining physical functioning in pediatric subjects undergoing chemotherapy and childhood cancer treatment18 month periodInvestigate if 30 minutes of exercise, five days per week, will have benefit relative to the control arm by increasing and/or maintaining physical functioning in pediatric subjects undergoing chemotherapy and childhood cancer treatment as measured by 6-Minute Walk test

Secondary

MeasureTime frameDescription
Adverse Event Rateup to 18 monthsOccurrence of Adverse Events of Special Interest (thromboembolic event, skin ulceration, significant nausea/vomiting, and constipation) will be measured as binary variables.
Quality of Life measured by the PedsQL Cancer Moduleup to 18 monthsInvestigate if a structured exercise regimen relative to the control arm will result in Increasing and /or maintaining quality of life as measured by the PedsQL Cancer Module. Peds QL scores will be calculated as a composite quantitative analogue variable ranging from zero (best score) to 100 (worst score).
Subject adherence to exercise regimenup to 18 monthsSubject adherence to exercise regimen will be determined by patient-reported tracker listing activity performed and duration of time of activity. Data collected will be normalized quantitatively based on intended activity.
Adverse Events Related to Exercise Programup to 18 monthsTo summarize adverse event rates deemed to be related to the protocol directed exercise program. Adverse events of special interest (Grade 2 or greater Bone fracture, Fall, and Muscle aches/Myalgia) will be captured for each subject and time point randomized to the intervention arm.

Countries

United States

Contacts

CONTACTMeg Lattanze
Megan.Lattanze@advocatehealth.org(980) 442-4239
PRINCIPAL_INVESTIGATORJennifer Pope, MD

Wake Forest University Health Sciences

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 23, 2026